Record date for share split in BioGaia AB (publ) determined as 19 May 2022
At BioGaia’s Annual General Meeting held earlier today, on 6 May 2022, it was resolved on a share split of the company's existing 20,196,462 shares, whereupon each share, regardless of series, is divided into five new shares. The Board of Directors was authorised to decide on the record date for the share split.
The Board of Directors has decided that the record date for the share split will be Thursday 19 May 2022, which means that the last day for trading in shares prior to the share split will be Tuesday 17 May 2022. The first day for trading in shares post the share split will be Wednesday 18 May 2022.
The share split will be automatically implemented via Euroclear Sweden AB and no actions are required by the shareholders. In connection with the share split, the B share will take over the existing trading venue on Nasdaq Stockholm. The A share will remain unlisted.
In connection with the split, the company's shares have been assigned new ISIN codes as set out below:
A shares: SE0017769987
B shares: SE0017769995
After the share split the total number of shares in the company will amount to 100,982,310, whereof 3,703,340 A shares and 97,278,970 B shares.
Latest press releases from BioGaia:
06.05.2022 Annual General Meeting of BioGaia
06.05.2022 Interim Management Statement January – March 2022
25.04.2022 BioGaia’s result for first quarter to exceed market expectations
This disclosure contains information that BioGaia is obliged to make public pursuant to the Swedish Securities Markets Act (2007:528). The information was submitted for publication, through the agency of the contact person, on 06-05-2022 13:00 CET.
For more information, please contact
Isabelle Ducellier, CEO: +46 8 555 293 00
Alexander Kotsinas, Executive Vice President: +46 8 555 293 00
BioGaia is an innovative Swedish healthcare company that develops, markets and sells probiotic products with documented health benefits. The products are sold through local distribution partners in more than 100 countries worldwide. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap segment of Nasdaq Stockholm. biogaia.com